However, since TNBC represents a challenge for clinicians due to its poorer prognosis, lack of targeted therapies and high mortality in comparison to other breast cancer subtypes, we decided to examine the effects of Pak and CaMKII combined inhibition in the survival of TNBC cells. This evidence concerns the gene CAMK2G and breast cancer.